Rifabutin
DefinitionThis section has been translated automatically.
IndicationThis section has been translated automatically.
Limited indicationThis section has been translated automatically.
Dosage and method of useThis section has been translated automatically.
Tuberculosis (combination therapy): 150 mg/day p.o., in case of immunosuppression 300 mg/day p.o.
MAI: 300 mg/day p.o. for up to 6 months after achieving negative cultures; in combination with clarithromycin, other macrolides or triazole antifungals 300 mg/day. In combination with indinavir: 150 mg/day p.o.
MAI prophylaxis: 300 mg/day p.o.
Reminder. Patients with soft contact lenses must be informed about the possibility of permanent discolouration of the lenses!
Undesirable effectsThis section has been translated automatically.
InteractionsThis section has been translated automatically.
ContraindicationThis section has been translated automatically.
PreparationsThis section has been translated automatically.
TablesThis section has been translated automatically.
Major interactions of rifabutin
Quinidine |
Quinidine effect ↓ |
Clarithromycin |
Rifabutin toxicity (plasma levels around 80% ↑, possibly dose reduction). |
Cotrimoxazole |
Cotrimoxazole effect ↓ |
Coumarins |
Coumarin effect ↓ |
Dapsone |
Dapsone effect ↓ |
Didanosine |
Palpitations, tachycardia |
Fluconazole |
Rifabutin levels around 80% ↑, possible dose adjustment. |
Glucocorticoids |
Glucocorticoid effect ↓ |
Cardiac glycosides |
Cardiac glycoside effect ↓ |
Contraceptives, oral |
contraceptive effect ↓ |
L-methadone |
L-methadone effect ↓ |
Opioids |
Opioid effect ↓ |
Phenytoin |
Phenytoin effect ↓ |
Sulfonylurea effect ↓ |